Categories Uncategorized

First-of-a-Kind Study Identifies Benefits of Group Psychedelic-Assisted Therapy Sessions

Psychedelics have become a popular topic of conversation, as well as of indulgence. While most of these substances remain outlawed in many countries across the globe, this has apparently not stopped people from accessing or using them.

One of the reported common ways of consuming these drugs is in groups. Until recently, however, there hasn’t been any data to measure the possible value an individual derived from a group psychedelic experience. That has now changed. A new study that was published recently has found that using psychedelics within group settings (retreats or religious ceremonies, for example), could trigger increases in social connectedness and positive well-being, as well as additional improvements to an individual’s mental health.

This study was led by doctoral student Hannes Kettner and was carried out by a group of researchers from the Imperial College London. The study recruited 886 participants in total who were required to take part in a guided group ceremony or experience that involved the voluntary consumption of one psychedelic substance, such as psilocybin or ayahuasca. Participants were also asked to fill out a number of virtual/online surveys, including a survey one to two weeks before their psychedelic experience; a second survey taken a couple of hours prior to the ceremony; the third survey on the day following the experience, and subsequent surveys one day and one month later.

Kettner revealed that in many self-selected studies on psychedelics, there existed a notable sampling bias, specifically toward subjects who were in their mid-20s and who had vast psychedelic experiences. He was surprised to observe that 40% of study participants signed up as people who were using psychedelics for the very first time, with the average age being 44.

This, he said, brings to mind the Michael Pollan effect, observing more individuals from differing social demographics picking interest in psychedelics, yet they did not necessarily want to access those substances by their own selves.

The study’s findings demonstrate that the effect of social settings when consuming psychedelics doesn’t just benefit an individual while on the psychedelic journey but can also bring about benefits that remain long after the experience.

Before the psychedelic ceremony, study subjects were asked to what extent they felt comfortable with the specific guides scheduled to be involved. This, Kettner stated, was one of the most reliable predictors of what kind of psychedelic experience came to pass for different individuals. He added that that while it was difficult to deduce direct comparisons between group and individual settings based on existing science, the researchers observed improvements in social connectedness as well as in participants’ well-being psychologically, which was similar to what had been observed in individual experiences.

As more becomes known about the therapeutic potential of psychedelics, many companies such as Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are investing in growing their capacity to rapidly meet the demand for commercial-scale medicines made from these substances.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://ibn.fm/PULL

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

6 days ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

2 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

4 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central…

4 weeks ago

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of…

4 weeks ago